Paragraph IV certification swaps a date for a lawsuit

Four boxes, not a free-text field

For each patent that claims the drug, or a use of it, listed in the Orange Book against the reference product an ANDA copies, the applicant has to certify one of four things: that no patent information has been filed for that drug at all (Paragraph I); that the listed patent has already expired (Paragraph II); that it will expire on a specific future date, with approval to be made effective on that date (Paragraph III); or that the patent is invalid, unenforceable, or won’t be infringed by the generic product (Paragraph IV). The certification isn’t a narrative description of the applicant’s view of the patent landscape — it’s a choice among four statutorily defined boxes, one per listed patent, and the box picked decides everything about what happens to that part of the application next.

Paragraphs I and II run straight through

An ANDA certified only under Paragraph I or Paragraph II carries no patent obstacle for FDA to clear: once the application otherwise meets the agency’s scientific and manufacturing requirements, FDA can approve it without waiting on anything patent-related, because the statute has already told the agency there’s no live patent standing between the application and approval. A Paragraph III certification is almost as clean procedurally, but it trades immediacy for a fixed date: FDA can make the approval itself effective on the patent’s expiration date, so the application can clear every other hurdle well ahead of time and still sit waiting on the calendar rather than on FDA’s own review queue.

Paragraph IV is the only one that has to tell the patent owner

A Paragraph IV certification carries a duty none of the other three impose: the applicant has to notify both the patent owner and the holder of the approved application the ANDA references, in a detailed statement laying out the factual and legal basis for believing the patent is invalid, unenforceable, or won’t be infringed. That notice isn’t a courtesy copy of the ANDA — it’s the document that starts the only clock this certification choice can trigger entirely on its own.

Forty-five days decides whether a 30-month stay follows

Once notified, the patent owner has 45 days to file an infringement suit. If no suit is filed in that window, FDA’s path to approving the Paragraph IV portion of the application opens up without that patent in the way. If a suit is filed within the 45 days, the statute imposes an automatic stay — up to 30 months from the date of notice — during which FDA generally can’t approve the application on the strength of that certification alone, regardless of how the underlying science review is going. The stay can end earlier if the litigation resolves first, or if a court shortens or lengthens it, but the default length is fixed by the statute itself, not by how long the lawsuit happens to take.

The same application can carry more than one box at once

Nothing requires an applicant to pick a single certification for an entire ANDA. A generic referencing a product with three listed patents can certify Paragraph II against one that’s already expired, Paragraph III against one with years left to run, and Paragraph IV against the one the applicant is prepared to contest — three separate certifications, three separate consequences, inside one application. A file that records “patent certification: Paragraph IV” as a single line for the whole submission has collapsed a patent-by-patent decision into a status that doesn’t actually exist in the statute.

Where this meets the file

A patent-certification worksheet that tracks each listed patent on its own line — which of the four boxes it drew, the notice date if that box was Paragraph IV, and the 45-day and 30-month dates that follow from it — is previewed in the launch catalog alongside this week’s other drug-lifecycle templates. If your program tracks a multi-patent certification differently, the shelf takes that correction directly.